VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
MNPR
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
MNPRMonopar Therapeutics Inc.
$71.97$482M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksMNPRBalance Sheet

Monopar Therapeutics Inc. (MNPR) Balance Sheet

11Y historyFree accessUpdated daily

The company carries effectively no debt, with a debt-to-equity ratio of 0.00 and a current ratio of 43.55 in 2026Q3, though total assets have contracted from $144.2M in 2025Q3 to $130.2M as cash has been consumed.

Income StatementBalance SheetCash FlowRatios

MNPR Balance Sheet

Annual statement

MNPR Balance Sheet

Monopar Therapeutics Inc. (MNPR) balance sheet — 11-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15
Total Current Assets129.88M140.46M60.29M7.33M13.17M20.52M16.8M13.23M7.32M9.13M2.1M2.03M
Cash & Short-Term Investments129.45M140.4M60.21M7.27M13.12M20.3M16.74M13.21M6.89M8.98M2.07M2.01M
Cash Only52.63M61.83M45.82M7.27M8.19M20.3M16.74M13.21M6.89M8.98M2.07M2.01M
Short-Term Investments76.81M78.57M14.4M04.93M0000000
Accounts Receivable000000000000
Days Sales Outstanding------------
Inventory000000000000
Days Inventory Outstanding------------
Other Current Assets434.87K63.74K78.87K66.43K45.98K217.75K62.69K15.71K0000
Total Non-Current Assets366.72K254.92K012.65K61.23K068.86K122.38K410.67K800.03K800.39K800K
Property, Plant & Equipment366.72K254.92K012.65K61.23K0000000
Fixed Asset Turnover0.00x-----------
Goodwill000000000000
Intangible Assets000000000730.65M00
Long-Term Investments0000000000800.39K800K
Other Non-Current Assets00000068.86K122.38K410.67K-729.85M00
Total Assets130.25M140.72M60.29M7.35M13.23M20.52M16.87M13.35M7.32M9.93M2.9M2.83M
Asset Turnover0.00x-----------
Asset Growth %424.8%133.4%720.83%-44.47%-35.55%21.66%26.34%82.46%-26.31%242.98%2.39%-
Total Current Liabilities2.98M2.74M5.25M1.76M3.13M1.58M1.18M724.16K399.55K311.87K64.51K73.84K
Accounts Payable2.82M2.74M2.25M1.76M3.13M1.58M1.18M724.16K399.55K311.87K64.51K73.84K
Days Payables Outstanding------------
Short-Term Debt000000000000
Deferred Revenue (Current)000000000000
Other Current Liabilities000000000000
Current Ratio43.55x51.35x11.47x4.17x4.21x12.98x14.28x18.27x18.32x29.28x32.48x27.46x
Quick Ratio43.55x51.35x11.47x4.17x4.21x12.98x14.28x18.27x18.32x29.28x32.48x27.46x
Cash Conversion Cycle------------
Total Non-Current Liabilities199.81K154.92K008.41K0000000
Long-Term Debt000000000000
Capital Lease Obligations594.12K154.92K008.41K0000000
Deferred Tax Liabilities000000000000
Other Non-Current Liabilities000000000000
Total Liabilities3.18M2.89M5.25M1.76M3.14M1.58M1.18M724.16K399.55K311.87K64.51K73.84K
Total Debt357.26K154.92K008.41K0000000
Net Debt-52.28M-61.68M-45.82M-7.27M-8.18M-20.3M-16.74M-13.21M-6.89M-8.98M-2.07M-2.01M
Debt / Equity0.00x0.00x--0.00x-------
Debt / EBITDA-0.02x-----------
Net Debt / EBITDA2.54x-----------
Interest Coverage---------32.27x-343.07x-163.83x-
Total Equity127.07M137.83M55.04M5.59M10.09M18.94M15.69M12.63M6.92M9.62M2.83M2.75M
Equity Growth %443.5%150.43%884.95%-44.62%-46.73%20.71%24.26%82.53%-28.08%239.78%2.79%-
Book Value per Share14.8418.604.790.390.791.521.431.190.660.920.290.34
Total Shareholders' Equity127.07M137.83M55.04M5.59M10.09M18.94M15.69M12.63M6.92M9.62M2.83M2.75M
Common Stock6.76K6.69K6.1K14.9K12.95K12.6K11.45K10.59K9.29K9.29K00
Retained Earnings-104.91M-89.51M-75.79M-60.21M-51.8M-41.29M-32.19M-25.88M-21.66M-18.43M-1.87M-687.31K
Treasury Stock000000000000
Accumulated OCI95.23K131.39K35.99K-14.13K8.94K-3.16K-7.87K-10.97K-2.4K000
Minority Interest000000000000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetAdequate
Cash FlowBurning
Top Statement Risk

Finite cash runway dependent on equity

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Cash-Funded Balance Sheet Expansion Reverses

According to reported quarterly balance sheets, MNPR's total assets rose from $53.9M in 2025Q2 to $144.2M in 2025Q3 before easing to $130.2M by 2026Q3, with equity tracking the same pattern and retained earnings deepening to -$104.9M.

The jump in assets during the second half of 2025 appears to reflect a capital raise rather than operating performance, since cash moved from $39.5M to $127.7M while liabilities remained modest. Since then, the balance sheet has been shrinking, with cash falling back to $52.6M, which suggests the company is consuming its funding faster than it is replenishing it. The steadily widening accumulated deficit confirms the trend is driven by sustained losses rather than any structural improvement in business quality.

Debt-Free Structure Limits Financing Options

Based on EDBL-style reported figures, MNPR carries effectively no debt, with total debt at $357.3K in 2026Q3 against equity of $127.1M, producing a debt-to-equity ratio of 0.00.

The absence of meaningful borrowing reduces refinancing and covenant risk, which is a genuine strength for a pre-revenue company without cash flow to service interest. However, the lack of debt also means the company has no leverage capacity to bridge funding gaps, leaving equity issuance as the realistic source of future capital. Investors should monitor how this dilution dependence interacts with the ongoing negative free cash flow.

Current Ratio Masks Shrinking Cash Cushion

As reported in the financial statements, MNPR's current ratio stands at 43.55 in 2026Q3, yet cash has declined from $61.8M at the end of 2025 to $52.6M, against quarterly operating cash burn of roughly $6M.

The very high current ratio reflects minimal current liabilities rather than a deep reservoir of liquid assets, so it overstates true financial flexibility. At the reported burn rate, the remaining cash implies a runway of roughly eight to nine quarters before additional capital is needed, though this estimate is sensitive to trial spending changes. The liquidity position is adequate in the near term but warrants close monitoring as the clinical programs advance.

Equity Base Eroded by Accumulated Losses

Based on reported equity figures, MNPR's shareholders' equity fell from $141.6M in 2025Q3 to $127.1M in 2026Q3, while retained earnings deteriorated from -$84.3M to -$104.9M over the same period.

The equity base is being drawn down almost entirely by operating losses, with no offsetting retained profits or revenue generation. The small buyback recorded in 2026Q1 is immaterial relative to the equity base and does not signal meaningful capital return. Equity quality therefore depends on the company's ability to raise future capital at acceptable prices to fund the pipeline.

Asset Quality Limited by Data Gaps

Based on the supplied balance sheet series, the headline asset base is dominated by cash, with goodwill and deferred revenue both reported at zero, but several quarterly figures show abrupt swings that may warrant further verification.

The sharp move in total assets between 2025Q2 and 2025Q3 is larger than the operating loss would explain, so the composition of that increase should be verified against the underlying filings. Because the company reports no goodwill and no deferred revenue, the balance sheet carries little impairment or forward-visibility risk, which keeps the analysis focused on cash burn. Investors should treat the cash balance as the critical asset and monitor it closely.

MNPR — Frequently Asked Questions

Quick answers to the most common questions about buying MNPR stock.

What are the total assets of Monopar Therapeutics Inc. (MNPR)?

As of 2025, Monopar Therapeutics Inc. (MNPR) had total assets of $140.7M including $140.5M in current assets.

How much debt does Monopar Therapeutics Inc. (MNPR) have?

Monopar Therapeutics Inc. (MNPR) carries total debt of $0.2M, offset by $140.4M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Monopar Therapeutics Inc.?

Monopar Therapeutics Inc. (MNPR) has total shareholders' equity (book value) of $137.8M ($18.60 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Monopar Therapeutics Inc.'s current ratio and liquidity?

Monopar Therapeutics Inc. (MNPR) reported a current ratio of 51.35x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.